Trial ID 20285 | Maryland Oncology Hematology Trial ID 20285 – Maryland Oncology Hematology

Trial ID 20285

Trial Information - Phase II

A Phase II Trial of Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Combination with Selinexor for Patients with Newly Diagnosed Multiple Myeloma

Protocol ID: IST-337

Sponsor: Karyopharm Therapeutics

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Multiple Myeloma

Investigator

Narang MD, Mohit

Status

OPEN TO ENROLLMENT

Sponsor

Karyopharm Therapeutics
« Clinical Trails Main

Quality Care Close to Home

View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology